Vincerx Pharma To Host Key Opinion Leader Webinar on Bioconjugation and CDK9 Inhibitors for the Treatment of Hematologic and Solid Tumors

PALO ALTO, Calif., April 07, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that it will be hosting a key opinion leader (KOL) meeting on bioconjugation and CDK9 inhibitors for the treatment of hematologic and solid tumors on Friday, April 16, 2021 at 12:00 PM ET.

The event will feature presentations by KOLs Brian Druker, M.D., Knight Cancer Institute, and Anthony W. Tolcher, M.D., NEXT Oncology™. Dr. Tolcher will discuss tackling normal tissue toxicity from antibody-drug conjugates (ADCs) and Dr. Druker will discuss CDK9 in hematologic malignancies. Drs. Druker and Tolcher will be available to answer questions following the formal presentations.

Vincerx’s management team will discuss its poster titled, “A novel small molecule drug conjugate -αvβ3 integrin antagonist linked to a cytotoxic camptothecin derivative- for the treatment of multiple cancer types,” which will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting, as well as the Company’s bioconjugation platform. Vincerx’s preclinical bioconjugation platform seeks to address the current limitations of small-molecule and antibody-drug conjugates in oncology and consists of VIP236, a small molecule drug conjugate (SMDC) targeting advanced and metastatic cancer, as well as VIP943 and VIP924, two ADCs targeting hematologic tumors.

To register for the webinar, please click here.

KOLs
Brian Druker, M.D., is the director of the Knight Cancer Institute, associate dean for oncology of the OHSU School of Medicine and the JELD-WEN Chair of Leukemia Research. His research is focused on translating the knowledge of the molecular pathogenesis of cancer into specific therapies and investigating the optimal use of these molecularly targeted agents. He performed preclinical studies that led to the development of imatinib (Gleevec) for chronic myeloid leukemia (CML) and then spearheaded the highly successful clinical trials of imatinib, which led to FDA approval of the drug in record time. This work changed the life expectancy of patients with CML from an average of 3 to 5 years to a 95% five-year survival and has resulted in a paradigm-shift in cancer treatment from non-specific chemotherapy to highly targeted therapeutic agents. He is a member of the National Academy of Medicine, the National Academy of Sciences and, among numerous awards, is the recipient of the 2009 Lasker-DeBakey Clinical Medical Research Award, the 2012 Japan Prize in Healthcare and Medical Technology and the 2019 Sjöberg Prize.

Anthony W. Tolcher, M.D. is CEO and Founder of NEXT Oncology™, San Antonio and Austin, Texas, Phase I group that seeks to transform early clinical trials. NEXT Oncology’s mission is to accelerate the next breakthrough medicines for cancer and the vision is to be the most successful and respected Phase I program in oncology research. Dr. Tolcher served as President and Co- Founder of START LLC from 2009- 2018, one of the world’s largest Clinical Phase I and early drug development operations in cancer medicine with 5 locations in San Antonio Texas; Grand Rapids, Michigan; Madrid Spain; and Shanghai China.

Dr. Tolcher is a medical oncologist who has over 25 years’ experience in early drug development and clinical trials. He has been involved in many of the initial phase I studies of new agents that subsequently were FDA approved for the treatment of cancer including pembrolizumab (Keytruda), copanlisib (Aliqopa), trastuzumab emtansine (Kadcyla), regorafenib (Stivarga), liposomal vincristine (Marqibo), cabazitaxel (Jevtana), carfilzomib (Kyprolis), gefitinib (Iressa), erlotinib (Tarceva), and eribulin (Halaven). He is currently the principal investigator on 40 phase I clinical studies, is a reviewer for the Journal of Clinical Oncology, Clinical Cancer Research, and Annals of Oncology. He has chaired the Developmental Therapeutics Review Committee for the American Association of Clinical Oncology Annual Scientific Program. Dr. Tolcher has over 100 peer-reviewed publications in scientific journals including Nature, Proceedings of the National Academy of Sciences (USA), Journal of Clinical Oncology, and Clinical Cancer Research, as well as an author of nine book chapters

About Vincerx Pharma, Inc.
Vincerx Pharma, Inc. (Vincerx) is a recently formed clinical-stage life sciences company focused on leveraging its extensive development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. Vincerx’s executive team has assembled a management team of biopharmaceutical experts with extensive experience in building and operating organizations that develop and deliver innovative medicines to patients. Vincerx’s current pipeline is derived from an exclusive license agreement with Bayer and includes a clinical-stage and follow-on small molecule drug program and a preclinical stage bioconjugation/next-generation antibody-drug conjugate platform. For more information, please visit www.vincerx.com.

Cautionary Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, expectations and events, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate” or other comparable terms. All statements other than statements of historical facts included in this press release are forward-looking statements. Forward-looking statements include, but are not limited to: Vincerx’s business model, pipeline, strategy, timeline and product candidates. Forward-looking statements are neither historical facts nor assurances of future performance or events. Instead, they are based only on current beliefs, expectations and assumptions regarding future business developments, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control.

Actual results, conditions and events may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results, conditions and events to differ materially from those indicated in the forward-looking statements include, but are not limited to: general economic, financial, legal, political and business conditions and changes in domestic and foreign markets; the potential effects of the COVID-19 pandemic; risks associated with preclinical or clinical development conducted prior to Vincerx’s in-licensing; failure to realize the anticipated benefits of the business combination with LifeSci Acquisition Corp.; failure to realize the benefits of Vincerx’s license agreement with Bayer; risks related to the rollout of Vincerx’s business and the timing of expected business milestones; changes in the assumptions underlying Vincerx’s expectations regarding its future business or business model; Vincerx’s ability to develop and commercialize product candidates; the availability and uses of capital; the effects of competition on Vincerx’s future business; and the risks and uncertainties set forth in Forms 10-K, 10-Q and 8-K filed with or furnished to the SEC from time to time by Vincerx. Forward -looking statements speak only as of the date hereof, and Vincerx disclaims any obligation to update any forward-looking statements.

Contacts
Bruce Mackle
LifeSci Advisors, LLC
646-889-1200
[email protected]